

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/073138 A1

(51) International Patent Classification:

C07K 19/00 (2006.01) C07K 16/10 (2006.01)
A61K 47/68 (2017.01) C07K 16/46 (2006.01)
A61P 31/14 (2006.01) C12N 15/13 (2006.01)
C07K 14/47 (2006.01) C12N 15/62 (2006.01)
C07K 16/00 (2006.01)

(21) International Application Number:

PCT/CA2021/051426

(22) International Filing Date:

08 October 2021 (08.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/089,782	09 October 2020 (09.10.2020)	US
63/197,236	04 June 2021 (04.06.2021)	US
63/220,929	12 July 2021 (12.07.2021)	US

(71) Applicant: **THE HOSPITAL FOR SICK CHILDREN**
[CA/CA]; 686 Bay Street, 3rd Floor, Toronto, Ontario M5G
0A4 (CA).

(72) Inventors: **JULIEN, Jean-Philippe**; 686 Bay Street, 3rd
Floor, Toronto, Ontario M5G 0A4 (CA). **RUJAS DIEZ,**
Edurne; 686 Bay Street, 3rd Floor, Toronto, Ontario M5G
0A4 (CA).

(74) Agent: **LOWTHERS, Erica L.** et al.; Aird & McBurney
LP, Brookfield Place, 181 Bay Street, Suite 1800, Toronto,
Ontario M5J 2T9 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: POLYPEPTIDES TARGETING SARS-COV-2 AND RELATED COMPOSITIONS AND METHODS




Figure 1

(57) Abstract: Provided herein is a fusion protein comprises a nanocage monomer linked to a SARS-CoV-2 binding moiety, wherein a plurality of the fusion proteins self-assemble to form a nanocage. Also provided is a tri-specific antibody construct targeting SARS-CoV-2. Also provided is a fusion polypeptide comprising (1) a fragment crystallizable (Fc) region linked to (2) a nanocage monomer or subunit thereof, wherein the Fc region comprises the I253A mutation, wherein numbering is according to the EU index.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*